

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)



(10) International Publication Number
WO 2023/146437 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61K 47/26* (2006.01)
A61K 47/02 (2006.01) *A61P 1/00* (2006.01)
A61K 47/10 (2017.01) *A61P 9/00* (2006.01)
A61K 47/12 (2006.01) *A61P 13/12* (2006.01)
A61K 47/18 (2017.01) *A61P 35/02* (2006.01)
A61K 47/22 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:

PCT/RU2023/050012

(22) International Filing Date:

31 January 2023 (31.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2022102193 31 January 2022 (31.01.2022) RU

(71) Applicant: **JOINT STOCK COMPANY «BIOCAD»**
[RU/RU]; vn. ter. g. poselok Strelna, p. Strelna, ul. Svyazi,
d. 38, str. 1, pomeshch. 89, Saint Petersburg, 198515 (RU).

(72) Inventors: **NIDZVEDSKII, Fedor Fandatovich**; pr-
kt Kosmonavtov, d.78, kv.41, Ekaterinburg, 620135
(RU). **OVCARENKO, Ekaterina Vladislavovna**; Ok-
tyabrskiy pr-kt, d. 5, kv. 78, Podolsk, 142117 (RU). **SO-
ZONOVA, Aleksandra Aleksandrovna**; Veteranov pr-
kt, d.169 corp. 2, kv.904, Saint Petersburg, 198205 (RU).
KOSTANDIAN, Alina Aleksandrovna; ul. Belysheva, d.
5/6, kv. 36, Saint Petersburg, 193313 (RU). **ANDREEVA,
Anastasiia Alekseevna**; ul. Tarasa Shevchenko, d. 33/45,
kv. 208, Saratov, 410056 (RU). **LOMKOVA, Ekaterina
Aleksandrovna**; Moskovskiy pr-kt, d. 216, kv. 19, Saint
Petersburg, 196066 (RU). **IAKOVLEV, Aleksandr Ole-
govich**; ul. Doneczkaya, d. 26, kv. 9, Moscow, 109651
(RU). **MOROZOV, Dmitry Valentinovich**; Admiralte-
jskij r-n, ul. Pochtamtskaja, d. 20, kv. 3, Saint Petersburg,
190000 (RU).

(74) Agent: **MELCHAEVA, Olga Anatolevna**; vn. ter. g.
poselok Strelna, p. Strelna, ul. Svyazi, d. 38, str. 1,
pomeshch. 89, Saint Petersburg, 198515 (RU).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: PHARMACEUTICAL COMPOSITION OF ANTI-TRBV9 ANTIBODY AND USE THEREOF

(57) Abstract: The invention relates to the field of pharmacy and medicine, specifically to pharmaceutical compositions of anti-TRBV9 antibody. The invention further relates to the use of said compositions for treating a disease or disorder mediated by T-lymphocytes bearing a TRBV9 segment within the T cell receptor, in a subject in need thereof.

WO 2023/146437 A1